Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jay Wohlgemuth

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Arthritis Research & Therapy|December 19, 2003
Microarray analysis of gene expression in lupusMary K Crow, Jay Wohlgemuth
Autoimmunity|February 27, 2004
Microarray analysis of interferon-regulated genes in SLEMary K Crow, Kyriakos A Kirou, Jay Wohlgemuth
Clinical Orthopaedics and Related Research|January 17, 2007
Distinct inflammatory gene pathways induced by particlesAndrew D Pearle, Mary K Crow, Diptendu S Rakshit, et al.
Circulation|October 22, 2014
Response to letter regarding article, "lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER trial (justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin)"Amit V Khera, Brendan M Everett, Michael P Caulfield, et al.
Circulation|November 19, 2013
Lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER Trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin)Amit V Khera, Brendan M Everett, Michael P Caulfield, et al.
Circulation|September 27, 2015
Atherogenic Lipoprotein Subfractions Determined by Ion Mobility and First Cardiovascular Events After Random Allocation to High-Intensity Statin or Placebo: The Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) TrialSamia Mora, Michael P Caulfield, Jay Wohlgemuth, et al.
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|July 5, 2005
Nodular endocardial infiltrates (Quilty lesions) cause significant variability in diagnosis of ISHLT Grade 2 and 3A rejection in cardiac allograft recipientsCharles C Marboe, Margaret Billingham, Howard Eisen, et al.
BMC Health Services Research|December 1, 2019
Dementia assessment and management in primary care settings: a survey of current provider practices in the United StatesAlissa Bernstein, Kirsten M Rogers, Katherine L Possin, et al.
Journal of Clinical Lipidology|March 25, 2020
Comparison of nonfasting and fasting lipoprotein subfractions and size in 15,397 apparently healthy individuals: An analysis from the VITamin D and OmegA-3 TriaLZareen M Farukhi, Olga V Demler, Michael P Caulfield, et al.
Contemporary Clinical Trials|November 1, 2019
Serum 25-hydroxyvitamin D in the VITamin D and OmegA-3 TriaL (VITAL): Clinical and demographic characteristics associated with baseline and change with randomized vitamin D treatmentHeike Luttmann-Gibson, Samia Mora, Carlos A Camargo, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Arthritis Research & Therapy|December 19, 2003
Microarray analysis of gene expression in lupusMary K Crow, Jay Wohlgemuth
Autoimmunity|February 27, 2004
Microarray analysis of interferon-regulated genes in SLEMary K Crow, Kyriakos A Kirou, Jay Wohlgemuth
Clinical Orthopaedics and Related Research|January 17, 2007
Distinct inflammatory gene pathways induced by particlesAndrew D Pearle, Mary K Crow, Diptendu S Rakshit, et al.
Circulation|October 22, 2014
Response to letter regarding article, "lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER trial (justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin)"Amit V Khera, Brendan M Everett, Michael P Caulfield, et al.
Circulation|November 19, 2013
Lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER Trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin)Amit V Khera, Brendan M Everett, Michael P Caulfield, et al.
Circulation|September 27, 2015
Atherogenic Lipoprotein Subfractions Determined by Ion Mobility and First Cardiovascular Events After Random Allocation to High-Intensity Statin or Placebo: The Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) TrialSamia Mora, Michael P Caulfield, Jay Wohlgemuth, et al.
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|July 5, 2005
Nodular endocardial infiltrates (Quilty lesions) cause significant variability in diagnosis of ISHLT Grade 2 and 3A rejection in cardiac allograft recipientsCharles C Marboe, Margaret Billingham, Howard Eisen, et al.
BMC Health Services Research|December 1, 2019
Dementia assessment and management in primary care settings: a survey of current provider practices in the United StatesAlissa Bernstein, Kirsten M Rogers, Katherine L Possin, et al.
Journal of Clinical Lipidology|March 25, 2020
Comparison of nonfasting and fasting lipoprotein subfractions and size in 15,397 apparently healthy individuals: An analysis from the VITamin D and OmegA-3 TriaLZareen M Farukhi, Olga V Demler, Michael P Caulfield, et al.
Contemporary Clinical Trials|November 1, 2019
Serum 25-hydroxyvitamin D in the VITamin D and OmegA-3 TriaL (VITAL): Clinical and demographic characteristics associated with baseline and change with randomized vitamin D treatmentHeike Luttmann-Gibson, Samia Mora, Carlos A Camargo, et al.
Pageof 2